PharmaLegacy Laboratories
Preclinical pharmacology CRO in Shanghai with specialty efficacy models in autoimmunity, inflammation, bone and orthopedics, oncology and metabolic disease, plus supporting PK/PD and exploratory toxicology.
46 contract research organizations in our directory list a site in Asia Pacific, across 6 countries. 29 report GLP capability and 10 report AAALAC accreditation. Compare services, species and accreditations below, and contact labs directly from their profiles.
Asia Pacific has become a major source of preclinical capacity. China and India host large integrated discovery and toxicology providers, Japan and South Korea have established GLP labs serving domestic and global sponsors, and Australia is often used for early clinical work that follows preclinical studies.
Regulatory status differs across the region: Japan, South Korea, Australia, New Zealand, India and Singapore adhere to the OECD Mutual Acceptance of Data system, while China does not fully adhere. Check inspection history and data acceptance for the regulator you plan to file with.
Among the CROs listed in Asia Pacific, the most common services are In Vivo Efficacy, GLP Toxicology, Toxicology and Pharmacokinetics. The species they most often work with are Mouse, Rat and Dog.
Showing 46 CROs with a site in Asia Pacific. Order rotates daily so no lab is permanently listed first.
Preclinical pharmacology CRO in Shanghai with specialty efficacy models in autoimmunity, inflammation, bone and orthopedics, oncology and metabolic disease, plus supporting PK/PD and exploratory toxicology.
Japanese preclinical CRO offering GLP safety and efficacy studies for drugs, devices and regenerative products, with long minipig experience.
Beijing-based company providing genetically engineered and humanized mouse models with in vivo pharmacology services, especially for oncology and immunology antibody programs.
Government-funded Korean research institute providing GLP nonclinical safety studies, including inhalation toxicology, safety pharmacology and reproductive toxicity.
Bengaluru-based preclinical CRO, part of Eurofins, offering GLP safety assessment, DMPK and discovery services for pharmaceutical and agrochemical sponsors.
Korean nonhuman primate CRO in the Biotoxtech group with GLP repeat-dose toxicity and cardiovascular safety pharmacology in NHPs, plus NHP inhalation studies.
Bengaluru preclinical CRO providing pharmacology, pharmacokinetic and toxicology studies.
Preclinical oncology and immuno-oncology CRO with orthotopic and metastatic models, whole-body imaging and GLP toxicology, with sites in Australia and the US.
Indian GLP test facility offering regulatory toxicology studies for chemicals, agrochemicals and pharmaceuticals.
Hyderabad discovery services company offering biology and DMPK support alongside chemistry.
South Korea's first private non-clinical CRO, providing GLP toxicity, safety pharmacology, pharmacokinetic and efficacy studies for drugs, chemicals and biologics.
Long-established Japanese preclinical CRO providing toxicology, carcinogenicity, genetic toxicity and pharmacology studies.
Korean CRO covering GLP toxicity, PK and efficacy studies through to clinical trials for drugs, devices and other products.
Indian GLP CRO providing regulatory toxicology and safety studies for pharmaceuticals, agrochemicals, chemicals and biologics.
Korean non-clinical CRO offering IND and NDA-enabling GLP toxicology, including general, reproductive and genetic toxicity, carcinogenicity and safety pharmacology, with NHP capacity through its group companies.
Indian GLP-certified preclinical CRO providing toxicology and safety studies.
Large China-based nonclinical CRO offering GLP safety assessment, pharmacology, pharmacokinetics and bioanalysis, with operations in China and the United States.
Korean non-clinical CRO focused on efficacy testing of new drug candidates, with research facilities in Songdo, Incheon.
Integrated discovery and development services company in India offering in vivo pharmacology, DMPK, bioanalysis and safety assessment alongside chemistry and biologics services.
Wuhan CRO integrating NHP breeding with toxicity and safety evaluation, PK/PD, molecular imaging and bioanalysis.
Australian bioanalytical and toxicology CRO with OECD GLP labs, supporting nonclinical toxicology and clinical bioanalysis.
AAALAC-accredited Japanese CRO specializing in nonhuman primate disease models for preclinical efficacy and proof of concept.
Beijing-based preclinical CRO focused on GLP safety evaluation, with branches across China and support for biologics, nucleic acid and cell and gene therapies.
Indian integrated drug discovery CRO offering in vivo pharmacology and DMPK alongside chemistry and biology.
Japanese company offering humanized-liver mice and contract studies for human metabolism, DMPK and hepatitis research.
Shanghai-based nonclinical CRO with GLP safety evaluation, pharmacology, DMPK, bioanalysis and biomarker services for small molecules, biologics and cell and gene therapies, operating several sites in China.
Global R&D services including discovery, DMPK, toxicology, bioanalysis, and manufacturing support.
OECD GLP-certified preclinical CRO near Bengaluru providing regulatory toxicology for pharmaceuticals, biologics, devices and chemicals.
Bengaluru CRDMO offering discovery services including DMPK, safety and bioanalysis alongside development and manufacturing.
Shanghai provider of genetically engineered rodent models with phenotyping and in vivo pharmacology services.
Shanghai oncology CRO with patient-derived xenograft and other tumor models for efficacy studies.
Chinese provider of genetically engineered mouse models with in vivo pharmacology services across oncology, immunology and metabolic disease.
Southwest China pharmacology CRO specializing in nonhuman primate efficacy, PK/PD and exploratory safety studies.
Tokyo CRO known for NASH/MASH and fibrosis mouse models, with efficacy studies across liver, kidney and metabolic disease.
Shanghai CRO centered on nonhuman primate efficacy and safety studies, with NHP disease models across metabolism, cardiovascular, renal, neurology and ophthalmology, clinical-style imaging and interventional surgery.
Long-established Japanese CRO with large GLP nonclinical safety facilities and deep nonhuman primate experience, supporting toxicology, safety pharmacology and pharmacokinetics.
Hyderabad-based preclinical CRO offering GLP toxicology, pharmacology and pharmacokinetic studies across rodent and non-rodent species.
Korean nonclinical pharmacology CRO in the Biotoxtech group offering efficacy studies, PCR-based biodistribution for cell and gene therapies, and GLP bioanalysis.
Korean nonclinical CRO providing early PK, TK and bioanalytical method development and sample analysis.
Integrated CRO-CDMO in India whose discovery biology group provides in vivo pharmacology, DMPK and bioanalysis for small molecule programs.
For a full checklist, see our CRO selection guide.